Stratec Biomedical AG

Stratec Biomedical AG (Stratec) is a Germany-based company engaged in the development and manufacture of fully automated systems based on its own patented technologies for its partners in the fields of clinical diagnostics and biotechnology. It is primarily active in the in vitro diagnostics industry and focuses on the segment in-vitro diagnostics, clinical diagnostics as well as molecular diagnostics. STRATEC’s partners market Company’s products to pharmaceutical laboratories, blood banks and research institutes throughout the world. STRATEC Group operates through its four consolidated subsidiaries in Switzerland, the United Kingdom, Germany as well as the United States, comprising STRATEC Biomedical Switzerland AG, STRATEC Biomedical UK, Ltd, STRATEC Molecular GmbH and STRATEC Biomedical USA, Inc.

Executive
Marcus Wolfinger
Full List of Officers

Fred Brueckner
Chairman of the Supervisory Board
Start date: 2000-3-

Marcus Wolfinger
Chairman of the Management Board, Chief Executive Officer
Start date: 1999-7-1

Rainer Baule
Vice Chairman of the Supervisory Board

Robert Siegle
Director of Finance and Human Resources, Member of the Board of Management

Claus Vielsack
Member of the Management Board, Director of Product Development
Start date: 2014-2-15

Stefanie Remmele
Member of the Supervisory Board

Date of incorporation
Country of incorporation
Phone +49 7082 79160
Fax +49 7082 7916999
Investor relations contact

+49 7082 79166515

Free float 7006905
Security description Common Stock
Main venue XETRA
Ticker at main venue SBS
Location

Gewerbestr. 37
75217 BIRKENFELD

Share price
/
 
Earnings per share
=
35.99
(
 
Share price
x
 
Shares
+
 
Net debt
) /
 
EBIT
=
INF
Price
x
 
Shares
/
 
Net Sales
=
2.1
(
 
Share price
x
 
Shares
+
 
Net debt
) /
 
Net sales
=
2.26
Price
x
 
Shares
/
 
Own capital
=
7.03
Earnings per share
x
 
Shares
/
 
Own capital
=
0.2%
Dividend per share
/
 
Price
=
-0.01%
2017 2016 2015 2014 2013
Income statement
Revenue 209.76 184.91 146.89 144.86 127.95
Other Revenue, Total
Total Revenue 209.76 184.91 146.89 144.86 127.95
Revenue Change 13.4% 25.9% 1.4% 13.2% 4.3%
Cost of Revenue, Total 141.41 122.97 91.80 99.92 86.19
Gross Profit 68.36 61.94 55.08 44.94 41.76
Selling/General/Admin. Expenses, Total 33.90 28.77 18.40 17.11 15.96
EBITDA 33.70 31.65 34.80
EBITDA margin (%) 16.1% 17.1% 23.7%
Research & Development 10.26 8.05 8.34 5.02 5.05
Depreciation/Amortization 0.25
Interest Exp.(Inc.),Net-Operating, Total
Unusual Expense (Income) 2.05 0.38 1.15
Other Operating Expenses, Total -1.29 1.14 0.74 -1.25 1.26
Total Operating Expense 180.92 160.78 120.01 120.81 108.46
Operating Income 28.84 24.13 26.88 24.05 19.49
EBIT margin (%) 23.5%
Interest Inc.(Exp.),Net-Non-Op., Total
Gain (Loss) on Sale of Assets
Other, Net -0.08 -0.08 -0.03 -0.04 -0.09
Net Income Before Taxes 28.03 22.85 27.17 24.05 19.33
Provision for Income Taxes 2.39 3.35 5.09 4.29 3.86
Net Income After Taxes 25.64 19.50 22.08 19.77 15.48
Minority Interest
Equity In Affiliates
U.S. GAAP Adjustment
Net Income Before Extra. Items 25.64 19.50 22.08 19.77 15.48
Total Extraordinary Items
Net Income 25.64 19.50 22.08 19.77 15.48
Total Adjustments to Net Income 0.00
Income Available to Com Excl ExtraOrd 25.64 19.50 22.08 19.77 15.48
Income Available to Com Incl ExtraOrd 25.64 19.50 22.08 19.77 15.48
Dilution Adjustment 0.00 0.00 0.00 0.00 0.00
Diluted Net Income 25.64 19.50 22.08 19.77 15.48
Diluted Weighted Average Shares 11.98 11.94 11.92 11.83 11.78
Diluted EPS Excluding ExtraOrd Items 2.14 1.63 1.85 1.67 1.31
DPS - Common Stock Primary Issue 0.80 0.77 0.75 0.70 0.60
Diluted Normalized EPS 2.44 1.66 1.93 1.69 1.38
Balance sheet
Cash 20.73
Cash & Equivalents 24.14 26.50 56.42 46.64
Short Term Investments 12.50 4.21 1.51 0.40 0.32
Cash and Short Term Investments 36.64 30.71 57.92 47.04 21.06
Accounts Receivable - Trade, Net 39.13 38.89 24.05 18.96 23.37
Total Receivables, Net 50.31 48.11 32.10 23.80 29.24
Total Inventory 27.88 24.52 16.02 18.07 18.09
Prepaid Expenses
Other Current Assets, Total 2.16 2.59 2.11 1.10 0.94
Total Current Assets 116.98 105.93 108.15 90.01 69.33
Property/Plant/Equipment, Total - Gross 61.64 54.11 37.10 31.93 31.92
Accumulated Depreciation, Total -25.94 -21.32 -17.01 -15.36 -14.40
Property/Plant/Equipment, Total - Net 35.70 32.79 19.60 15.95 17.01
Goodwill, Net 42.02 42.84 5.13 4.79 4.43
Intangibles, Net 68.71 75.94 25.87 25.48 25.76
Long Term Investments 0.24 0.38 0.18 0.26 0.39
Note Receivable - Long Term
Other Long Term Assets, Total 0.13 0.10 0.02 1.26 0.87
Total Assets 263.78 257.97 158.94 137.75 117.79
Accounts Payable 6.93 7.10 3.44 2.82 4.40
Payable/Accrued
Accrued Expenses 14.29 9.60 5.52 2.39 3.27
Notes Payable/Short Term Debt 0.00 0.00 0.00 0.00 0.00
Current Port. of LT Debt/Capital Leases 0.97 69.01 1.49 4.63 1.90
Other Current liabilities, Total 6.51 8.49 8.22 5.75 3.00
Total Current Liabilities 28.70 94.20 18.67 15.59 12.56
Long Term Debt 61.53 2.51 3.61 4.48 6.64
Capital Lease Obligations
Total Long Term Debt 61.53 2.51 3.61 4.48 6.64
Total Debt 62.51 71.51 5.11 9.12 8.54
Deferred Income Tax 11.04 14.57 5.58 5.57 1.39
Minority Interest
Other Liabilities, Total 4.67 4.35 0.80 0.06 0.01
Total Liabilities 105.94 115.63 28.66 25.70 20.61
Redeemable Preferred Stock, Total
Preferred Stock - Non Redeemable, Net
Common Stock, Total 11.92 11.86 11.85 11.80 11.77
Additional Paid-In Capital 22.42 20.44 20.06 18.13 17.22
Retained Earnings (Accumulated Deficit) 121.06 104.55 94.31 80.48 67.77
Treasury Stock - Common -0.09 -0.12 -0.17 -0.21 -0.21
ESOP Debt Guarantee
Unrealized Gain (Loss) 2.53 1.04
Other Equity, Total 0.01 4.57 4.23 1.86 0.64
Total Equity 157.84 142.34 130.28 112.05 97.18
Total Liabilities & Shareholders Equity 263.78 257.97 158.94 137.75 117.79
Total Common Shares Outstanding 11.92 11.85 11.84 11.78 11.76
Total Preferred Shares Outstanding
Tangible Book Value per Share, Common Eq 3.95 1.99 8.38 6.94 5.70
Cashflow
Net Income/Starting Line 25.64 19.50 22.08 19.77 15.48
Depreciation/Depletion 18.49 11.21 6.23 8.20 6.57
Amortization
Deferred Taxes -4.09 -3.19 1.13 3.86 1.06
Non-Cash Items 3.04 7.77 3.01 0.06 2.99
Changes in Working Capital -13.09 -18.98 -6.35 7.87 -2.17
Cash from Operating Activities 29.98 16.31 26.11 39.75 23.92
Capital Expenditure -15.67 -9.98 -8.86 -6.69 -10.09
Other Investing Cash Flow Items, Total 0.03 -76.75 0.15 -0.13 -0.20
Cash from Investing Activities -15.64 -86.73 -8.71 -6.82 -10.29
Financing Cash Flow Items
Total Cash Dividends Paid -9.13 -8.89 -8.25 -7.06 -6.57
Issuance (Retirement) of Stock, Net 1.81 0.25 1.67 0.69 0.80
Issuance (Retirement) of Debt, Net -8.66 49.24 -2.09 -1.65 -0.07
Cash from Financing Activities -15.98 40.61 -8.66 -8.01 -5.83
Foreign Exchange Effects -0.73 -0.10 1.04 0.98 -0.27
Net Change in Cash -2.36 -29.92 9.78 25.90 7.53
Cash Interest Paid 1.04 0.60 0.14 0.19 0.22
Cash Taxes Paid 2.13 6.60 6.38 -1.00 3.28
Values are in EUR and expressed in million